Published online before print September 15, 2005, doi: 10.1161/01.RES.0000186194.06514.b0
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 18, 2005
Revised on August 9, 2005
Accepted on September 1, 2005
Noonan Syndrome Mutation Q79R in Shp2 Increases Proliferation of Valve Primordia Mesenchymal Cells via Extracellular Signal-Regulated Kinase 1/2 Signaling
Maike Krenz ;
From the Children’s Hospital Research Foundation, Cincinnati, Ohio.
* To whom correspondence should be addressed. E-mail: jeff.robbins{at}cchmc.org.
The molecular pathways regulating valve development are only partially understood. Recent studies indicate that dysregulation of mitogen-activated protein kinase (MAPK) signaling might play a major role in the pathogenesis of congenital valvular malformations, and, in this study, we explored the role of extracellular signal-regulated kinase (ERK) 1/2 activation in valve primordia expressing the Noonan syndrome mutation Q79R-Shp2. Noonan syndrome is an autosomal dominant disease characterized by dysmorphic features and cardiac abnormalities, with frequent pulmonic stenosis. The Q79R mutation of PTPN11 previously identified in Noonan syndrome families results in a gain-of-function of the encoded protein tyrosine phosphatase Shp2. We compared the effects of wild-type Shp2 and Q79R-Shp2 on endocardial cushion development. Atrioventricular and outflow tract endocardial cushions were excised from chick embryos, infected with wild-type Shp2 or Q79R-Shp2 adenovirus and embedded in a gel matrix. Q79R-Shp2, but not wild-type-Shp2, expression resulted in increased outgrowth of cells into the gel. The dependence of the Q79R-Shp2 effect on ERK1/2 and p38 MAPK signaling was then determined. The MAPK/ERK (MEK)-1 inhibitor U0126, but not the p38-MAPK pathway inhibitor SB203580, abolished the effect of Q79R-Shp2 on cushion outgrowth. Coinfection with Q79R-Shp2 and dominant negative MEK-1 prevented enhanced endocardial cushion outgrowth, whereas expression of constitutively active MEK-1 mimicked the effect of Q79R-Shp2. Furthermore, dissociated cushion cells displayed increased 5-bromodeoxyuridine incorporation when infected with Q79R-Shp2 but not with wild-type Shp2. This promitotic effect was eliminated by U0126. Our results demonstrate that ERK1/2 activation is both necessary and sufficient to mediate the hyperproliferative effect of a gain-of-function mutation of Shp2 on mesenchymal cells in valve primordia.
Key words: phosphatase • development • valve stenosis • endocardial cushion
This article has been cited by other articles:
 |
|
 |
|
  M. D. Combs and K. E. Yutzey VEGF and RANKL Regulation of NFATc1 in Heart Valve Development Circ. Res., September 11, 2009; 105(6): 565 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Combs and K. E. Yutzey Heart Valve Development: Regulatory Networks in Development and Disease Circ. Res., August 28, 2009; 105(5): 408 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Araki, G. Chan, S. Newbigging, L. Morikawa, R. T. Bronson, and B. G. Neel Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation PNAS, March 24, 2009; 106(12): 4736 - 4741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Stevens, D. M. Broka, P. Parker, E. Rogowitz, R. R. Vaillancourt, and T. D. Camenisch MEKK3 Initiates Transforming Growth Factor {beta}2-Dependent Epithelial-to-Mesenchymal Transition During Endocardial Cushion Morphogenesis Circ. Res., December 5, 2008; 103(12): 1430 - 1440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Krenz, J. Gulick, H. E. Osinska, M. C. Colbert, J. D. Molkentin, and J. Robbins Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome PNAS, December 2, 2008; 105(48): 18930 - 18935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Eminaga and A. M. Bennett Noonan Syndrome-associated SHP-2/Ptpn11 Mutants Enhance SIRP{alpha} and PZR Tyrosyl Phosphorylation and Promote Adhesion-mediated ERK Activation J. Biol. Chem., May 30, 2008; 283(22): 15328 - 15338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang Mitogen-Activated Protein Kinases in Heart Development and Diseases Circulation, September 18, 2007; 116(12): 1413 - 1423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wagner and M. A. Q. Siddiqui Signal Transduction in Early Heart Development (II): Ventricular Chamber Specification, Trabeculation, and Heart Valve Formation Experimental Biology and Medicine, July 1, 2007; 232(7): 866 - 880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Gelb and M. Tartaglia Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction Hum. Mol. Genet., October 15, 2006; 15(suppl_2): R220 - R226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Kontaridis, K. D. Swanson, F. S. David, D. Barford, and B. G. Neel PTPN11 (Shp2) Mutations in LEOPARD Syndrome Have Dominant Negative, Not Activating, Effects J. Biol. Chem., March 10, 2006; 281(10): 6785 - 6792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Yutzey, M. Colbert, and J. Robbins Ras-Related Signaling Pathways in Valve Development: Ebb and Flow Physiology, December 1, 2005; 20(6): 390 - 397. [Abstract] [Full Text] [PDF]
|
|